BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2720890)

  • 1. Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma.
    Ajani JA; Goudeau P; Levin B; Faintuch JS; Abbruzzese JL; Boman BM; Kanojia MD
    Cancer Chemother Pharmacol; 1989; 24(1):41-4. PubMed ID: 2720890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.
    Bjarnason GA; Cripps C; Goel R; Fine S; Oza AM; Skillings JR; Kerr I; Germond CJ; Moore MJ; Maroun JA; Franssen E; Dulude H
    Am J Clin Oncol; 1998 Dec; 21(6):537-42. PubMed ID: 9856651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma.
    Dickinson R; Presgrave P; Levi J; Milliken S; Woods R
    Cancer Chemother Pharmacol; 1989; 24(1):67-8. PubMed ID: 2720894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study.
    Westermann AM; Taal BG; Swart M; Boot H; Craanen M; Gerritsen WR
    Pharmacol Res; 2000 Aug; 42(2):151-6. PubMed ID: 10887044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results with FAMTX (5-fluorouracil, adriamycin, methotrexate) in advanced gastric cancer.
    Klein HO
    Anticancer Res; 1989; 9(4):1025-6. PubMed ID: 2817784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
    Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
    J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer.
    Wils J; Bleiberg H; Dalesio O; Blijham G; Mulder N; Planting A; Splinter T; Duez N
    J Clin Oncol; 1986 Dec; 4(12):1799-803. PubMed ID: 3783204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancer.
    Roelofs EJ; Wagener DJ; Conroy T; Wils J; Burghouts JT; Fickers M; de Graeff A; Lalisang F; Paillot B
    Ann Oncol; 1993 May; 4(5):426-8. PubMed ID: 8353077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer.
    Wagener DJ; Yap SH; Wobbes T; Burghouts JT; van Dam FE; Hillen HF; Hoogendoorn GJ; Scheerder H; van der Vegt SG
    Cancer Chemother Pharmacol; 1985; 15(1):86-7. PubMed ID: 4039985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer.
    Takahashi S; Kinoshita T; Konishi M; Nakagouri T; Inoue K; Ono M; Sugitou M; Ohtsu A; Boku N; Yoshida S
    Gastric Cancer; 2001; 4(4):192-7. PubMed ID: 11846062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
    Felici A; Carlini P; Ruggeri EM; Gamucci T; Pollera CF; De Marco S; Fariello AM; Moscetti L; Gelibter A; Adami E; Sperduti I; Cognetti F
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):59-64. PubMed ID: 16001173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach.
    Cazap EL; Gisselbrecht C; Smith FP; Estevez RA; Alvarez CA; Lagarde C; Hannois A; Ahmed S; Schein PS; Woolley PV
    Cancer Treat Rep; 1986 Jun; 70(6):781-3. PubMed ID: 3524826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
    Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
    Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential high-dose methotrexate, 5-fluorouracil, and doxorubicin for treatment of advanced pancreatic cancer.
    Scheithauer W; Funovics J; Mueller C; Ludwig H
    J Cancer Res Clin Oncol; 1990; 116(2):132-3. PubMed ID: 2324155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
    Kollmannsberger C; Quietzsch D; Haag C; Lingenfelser T; Schroeder M; Hartmann JT; Baronius W; Hempel V; Clemens M; Kanz L; Bokemeyer C
    Br J Cancer; 2000 Aug; 83(4):458-62. PubMed ID: 10945491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma.
    Ajani JA; Mayer RJ; Ota DM; Steele GD; Evans D; Roh M; Sugarbaker DJ; Dumas P; Gray C; Vena DA
    J Natl Cancer Inst; 1993 Nov; 85(22):1839-44. PubMed ID: 8230264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.
    Kim YH; Shin SW; Kim BS; Kim JH; Kim JG; Mok YJ; Kim CS; Rhyu HS; Hyun JH; Kim JS
    Cancer; 1999 Jan; 85(2):295-301. PubMed ID: 10023695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.
    Murad AM; Santiago FF; Petroianu A; Rocha PR; Rodrigues MA; Rausch M
    Cancer; 1993 Jul; 72(1):37-41. PubMed ID: 8508427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.